ArticleApplied biochemistry and biotechnology2026
Erjingwan Alleviates Parkinson's Disease via Activation of PPARA-Mediated Autophagy.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Parkinson's disease (PD) is characterized by progressive dopaminergic neuronal degeneration and neuroinflammation. Traditional Chinese medicine (TCM) formulas exhibit potential neuroprotective effects, yet the active components and underlying mechanisms of Erjingwan (EJW) remain unclear. To elucidate the therapeutic mechanisms of EJW in PD by integrating network pharmacology with in vivo and in vitro experimental validation. PD mice were modeled using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Behavioral assessments, histological staining, immunohistochemistry, enzyme-linked immunosorbent assay (ELISA), and Western blotting were performed to evaluate neuronal injury, inflammation, and apoptosis. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used to identify EJW components. Network pharmacology and machine learning were applied to screen potential targets. Molecular docking and molecular dynamics simulations were conducted to assess component-target interactions. Adeno-associated virus (AAV)-mediated peroxisome proliferator-activated receptor alpha (PPARA) knockdown in vivo and short hairpin RNA (shRNA) interference in vitro were used for mechanistic validation. EJW significantly improved motor dysfunction in PD mice. EJW attenuated dopaminergic neuronal loss in the substantia nigra, suppressed neuroinflammation, and decreased cell apoptosis. LC-MS/MS identified 10 bioactive compounds. Integrated analysis yielded 83 potential targets, with PPARA identified as a key target by machine learning. Molecular docking and dynamics simulations indicated stable binding between multiple bioactive compounds and PPARA. EJW upregulated PPARA expression and promoted autophagy. PPARA knockdown inhibited autophagy and diminished the neuroprotective effects of EJW. EJW alleviates PD by activating PPARA-mediated autophagy. PPARA may serve as a critical therapeutic target of EJW in PD.
Indexed as
Identifiers
42584531What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.